Patents Assigned to BioNtech Cell & Gene Therapies GmbH
  • Claudin-18.2-specific immunoreceptors and T cell epitopes
    Patent number: 11713346
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 1, 2023
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON—Translationale Onkologie An Der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
  • Claudin-6-specific immunoreceptors and t cell epitopes
    Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 11311611
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: April 26, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenbera-Universität Mainz Gemeinnützine GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination
    Patent number: 10799534
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 13, 2020
    Assignees: BIONTECH CELL & GENE THERAPIES GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÁTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Ugur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
  • ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES
    Publication number: 20190060430
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicants: BioNTech Cell & Gene Therapies GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 10117918
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: November 6, 2018
    Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gmbh
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Antigen-specific T cell receptors and T cell epitopes
    Patent number: 9586997
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: March 7, 2017
    Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko